D.E. Shaw & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-10,000
Closed -$4.2M – 4449
2022
Q4
$4.2M Sell
10,000
-500
-5% -$202K ﹤0.01% 2255
2022
Q3
$4.38M Buy
10,500
+10,000
+2,000% +$4.99M 0.01% 2251
2022
Q2
$248K Sell
500
-10,600
-95% -$5.52M ﹤0.01% 4449
2022
Q1
$6.25M Sell
11,100
-13,000
-54% -$7.84M 0.01% 2066
2021
Q4
$18.2M Buy
24,100
+1,100
+5% +$823K 0.02% 1149
2021
Q3
$17.2M Buy
+23,000
New +$17.2M 0.02% 1123
2020
Q4
– Sell
-1,500
Closed -$773K – 3918
2020
Q3
$773K Hold
1,500
– – ﹤0.01% 3011
2020
Q2
$677K Buy
+1,500
New +$662K ﹤0.01% 3162
2019
Q3
– Sell
-7,600
Closed -$2.38M – 3810
2019
Q2
$2.38M Hold
7,600
– – ﹤0.01% 2127
2019
Q1
$2.32M Buy
+7,600
New +$2.05M ﹤0.01% 2051

Other funds holding BIO

D.E. Shaw & Co's BIO Position: Q3 2026 in Review

D.E. Shaw & Co increased its Bio-Rad Laboratories Class A (BIO) stake by 402% in Q3 2026, buying an estimated $27M and bringing the position to 96,719 shares worth $36.5M. The position accounts for 0.02% of the portfolio, ranked #946.

D.E. Shaw & Co first reported a position in BIO in Q2 2013 and has held it in 54 quarters since. The position peaked at $59.6M in Q3 2018. 419 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • D.E. Shaw & Co held 96,719 shares of Bio-Rad Laboratories Class A worth $36.5M as of Q3 2026.
  • D.E. Shaw & Co bought 77,463 Bio-Rad Laboratories Class A shares in Q3 2026, an estimated $27M.
  • Bio-Rad Laboratories Class A made up 0.02% of D.E. Shaw & Co's portfolio in Q3 2026, its #946 holding.
  • D.E. Shaw & Co first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 54 quarters since.
  • D.E. Shaw & Co's Bio-Rad Laboratories Class A position peaked at $59.6M in Q3 2018.
  • 419 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.